Vikram Purohit
Stock Analyst at Morgan Stanley
(0.76)
# 3,662
Out of 4,711 analysts
170
Total ratings
25.81%
Success rate
-15.14%
Average return
Main Sectors:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $10.01 | +249.65% | 2 | Dec 11, 2024 | |
| INCY Incyte | Maintains: Equal-Weight | $64 → $69 | $68.84 | +0.23% | 23 | Oct 30, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $5.14 | +75.10% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $20.31 | +52.63% | 2 | Sep 11, 2024 | |
| SLRN Acelyrin | Maintains: Equal-Weight | $13 → $6 | $3.15 | +90.48% | 7 | Aug 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $59 → $64 | $46.96 | +36.29% | 6 | Aug 7, 2024 | |
| ABSI Absci | Initiates: Overweight | $7 | $2.99 | +134.11% | 1 | Jul 3, 2024 | |
| ASND Ascendis Pharma | Maintains: Equal-Weight | $116 → $140 | $136.38 | +2.65% | 18 | May 16, 2024 | |
| AXSM Axsome Therapeutics | Upgrades: Overweight | $90 → $115 | $90.73 | +26.75% | 18 | Apr 29, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $7.65 | +109.15% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.97 | +655.67% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $22 | $5.61 | +292.16% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $14.99 | -33.29% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $2.24 | +167.86% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $7.62 | +451.18% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $6.03 | +82.42% | 1 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $23 | $2.02 | +1,013.86% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $40.66 | +0.84% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $20.61 | +94.08% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $1.51 | +760.93% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $19.44 | +95.47% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $10.71 | +86.74% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $9.59 | +4.28% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $7 | $15.52 | -54.90% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $2.97 | +640.74% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $3.19 | +526.96% | 2 | Aug 5, 2020 |
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $10.01
Upside: +249.65%
Incyte
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $64 → $69
Current: $68.84
Upside: +0.23%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $5.14
Upside: +75.10%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $20.31
Upside: +52.63%
Acelyrin
Aug 19, 2024
Maintains: Equal-Weight
Price Target: $13 → $6
Current: $3.15
Upside: +90.48%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Overweight
Price Target: $59 → $64
Current: $46.96
Upside: +36.29%
Absci
Jul 3, 2024
Initiates: Overweight
Price Target: $7
Current: $2.99
Upside: +134.11%
Ascendis Pharma
May 16, 2024
Maintains: Equal-Weight
Price Target: $116 → $140
Current: $136.38
Upside: +2.65%
Axsome Therapeutics
Apr 29, 2024
Upgrades: Overweight
Price Target: $90 → $115
Current: $90.73
Upside: +26.75%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $7.65
Upside: +109.15%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $3.97
Upside: +655.67%
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $5.61
Upside: +292.16%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $14.99
Upside: -33.29%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $2.24
Upside: +167.86%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $7.62
Upside: +451.18%
Jul 13, 2023
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $6.03
Upside: +82.42%
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $2.02
Upside: +1,013.86%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $40.66
Upside: +0.84%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $20.61
Upside: +94.08%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $1.51
Upside: +760.93%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $19.44
Upside: +95.47%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $10.71
Upside: +86.74%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $9.59
Upside: +4.28%
Dec 10, 2021
Downgrades: Underweight
Price Target: $18 → $7
Current: $15.52
Upside: -54.90%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $2.97
Upside: +640.74%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $3.19
Upside: +526.96%